BioTroy Therapeutics Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $27.8M

  • Investors
  • 13

BioTroy Therapeutics General Information

Description

Developer of immuno-oncology therapeutics designed to discover novel therapeutic targets and develop cancer treatments. The company offers tumour immunology research platforms, antibody discovery technologies, biopharmaceutical development capabilities, and companion diagnostic reagents, enabling oncology researchers, pharmaceutical companies, and healthcare providers to advance targeted cancer therapies and precision medicine programs.

Contact Information

Website
www.biotroy.cn
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 203, Building 1
  • Number 1227 Zhangheng Road, Pudong New Area
  • Shanghai, 201203
  • China
+86 021
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Pharmaceuticals
Vertical(s)
Corporate Office
  • Room 203, Building 1
  • Number 1227 Zhangheng Road, Pudong New Area
  • Shanghai, 201203
  • China
+86 021

BioTroy Therapeutics Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BioTroy Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Early Stage VC (Series A) 17-Jun-2025 $27.8M Completed Generating Revenue
4. Early Stage VC 28-Mar-2025 Completed Generating Revenue
3. Early Stage VC 31-Jan-2023 Completed Generating Revenue
2. Early Stage VC 19-Jan-2022 $15.7M $15.7M Completed Generating Revenue
1. Seed Round 29-Sep-2021 Completed Startup
To view BioTroy Therapeutics’s complete valuation and funding history, request access »

BioTroy Therapeutics Patents

BioTroy Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026189535-A1 Anti-cd3l1 antibody-drug conjugate and use thereof in preparation of anti-tumor drug Pending 14-Mar-2025
WO-2026189535-A9 Anti-cd3l1 antibody-drug conjugate and use thereof in preparation of anti-tumor drug Pending 14-Mar-2025
WO-2026061529-A1 Use of mageb16 modulator in preparation of product for treating autoimmune disease or resisting tumor Pending 23-Sep-2024
JP-7938962-B2 A method for suppressing tumor cell proliferation based on ccdc112 Active 08-Feb-2021
AU-2022216578-A1 Method for inhibiting tumour cell growth based on ccdc112 Pending 08-Feb-2021 C07K16/28
To view BioTroy Therapeutics’s complete patent history, request access »

BioTroy Therapeutics Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
Shanghai Industrial Capital Management Growth/Expansion Minority
ZhongMei Capital Venture Capital Minority
Lapam Capital Venture Capital Minority
Pudong Capital Venture Capital Minority
Shanghai Science and Technology Innovation Center Equity Investment Fund Management Fund of Funds Minority
You’re viewing 5 of 13 investors. Get the full list »

BioTroy Therapeutics FAQs

  • When was BioTroy Therapeutics founded?

    BioTroy Therapeutics was founded in 2020.

  • Where is BioTroy Therapeutics headquartered?

    BioTroy Therapeutics is headquartered in Shanghai, China.

  • What industry is BioTroy Therapeutics in?

    BioTroy Therapeutics’s primary industry is Biotechnology.

  • Is BioTroy Therapeutics a private or public company?

    BioTroy Therapeutics is a Private company.

  • What is BioTroy Therapeutics’s current revenue?

    The current revenue for BioTroy Therapeutics is .

  • How much funding has BioTroy Therapeutics raised over time?

    BioTroy Therapeutics has raised $69.8M.

  • Who are BioTroy Therapeutics’s investors?

    Shanghai Industrial Capital Management, ZhongMei Capital, Lapam Capital, Pudong Capital, and Shanghai Science and Technology Innovation Center Equity Investment Fund Management are 5 of 13 investors who have invested in BioTroy Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process